Adverse Event considerations for repositioning remdesivir, hydroxychloroquine, chloroquine, and interleukin (IL)-6 inhibitors in COVID-19 patients

June 19, 2020COVID-19, Vizit Graphs
Adverse Event considerations for repositioning remdesivir, hydroxychloroquine, chloroquine, and interleukin (IL)-6 inhibitors in COVID-19 patients

Patients with COVID-19 often also face cardiovascular challenges and associated comorbidities. Understanding how repositioned drugs to treat COVID-19 may impact the cardiovascular health of patients is important.Live Graph Detail: Targets of the drugs are included (e.g. RNA dependent RNA polymerase, target of remdesivir, IL-7, target of IL-6 inhibitors). Explore the live graph.